{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for amphotericin root_names_stdName in Standardized Name (approximate match)
Status:
Other
Class:
G1 SPECIFIED SUBSTANCE
Status:
Possibly Marketed Outside US
Source:
NDA217865
(2024)
Source URL:
First approved in 2016
Source:
ANDA091356
Source URL:
Class:
G1 SPECIFIED SUBSTANCE
Status:
Possibly Marketed Outside US
Source:
ANDA075679
(2003)
Source URL:
First approved in 2003
Source:
ANDA075679
Source URL:
Class:
G1 SPECIFIED SUBSTANCE
Status:
Possibly Marketed Outside US
First approved in 1987
Source:
M012
Source URL:
Class:
G1 SPECIFIED SUBSTANCE
Status:
US Approved Rx
(2014)
First approved in 2014
Class:
CONCEPT
Status:
US Approved Rx
(2014)
First approved in 2014
Class:
CONCEPT
Status:
US Approved Rx
(2014)
First approved in 2014
Class:
CONCEPT
Status:
US Approved Rx
(2015)
First approved in 2014
Class:
CONCEPT
Status:
US Approved Rx
(1989)
First approved in 1989
Class:
CONCEPT
Status:
Investigational
Source:
NCT03582033: Phase 1 Interventional Terminated Multiple Myeloma
(2018)
Source URL:
Class:
CONCEPT